# EDGAR Filing Document

**Accession Number:** 0001385508
**File Stem:** 0001193125-23-068421
**Filing Date:** 2023-3
**Character Count:** 3730
**Document Hash:** 02892bbb2cf9735f8401857409a9b6c5
**Contains OCR:** False
**Source Format:** 

## Filing Content

## Filing Summary
**0001193125-23-068421.hdr.sgml**: 20230313

**ACCESSION NUMBER**: 0001193125-23-068421

**CONFORMED SUBMISSION TYPE**: 15-12G

**PUBLIC DOCUMENT COUNT**: 1

**FILED AS OF DATE**: 20230313

**DATE AS OF CHANGE**: 20230313

**EFFECTIVENESS DATE**: 20230313

**FILER**: 

**COMPANY DATA:**
- **COMPANY CONFORMED NAME:** OPIANT PHARMACEUTICALS, INC.
- **CENTRAL INDEX KEY:** 0001385508
- **STANDARD INDUSTRIAL CLASSIFICATION:** PHARMACEUTICAL PREPARATIONS [2834]
- **IRS NUMBER:** 464744124
- **FISCAL YEAR END:** 1231

**FILING VALUES:**
- **FORM TYPE:** 15-12G
- **SEC ACT:** 1934 Act
- **SEC FILE NUMBER:** 001-38193
- **FILM NUMBER:** 23725612

**BUSINESS ADDRESS:**
- **STREET 1:** 233 WILSHIRE BLVD
- **STREET 2:** SUITE 400
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90401
- **BUSINESS PHONE:** (310) 598-5410

**MAIL ADDRESS:**
- **STREET 1:** 233 WILSHIRE BLVD
- **STREET 2:** SUITE 400
- **CITY:** SANTA MONICA
- **STATE:** CA
- **ZIP:** 90401

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Lightlake Therapeutics Inc.
- **DATE OF NAME CHANGE:** 20091009

**FORMER COMPANY:**
- **FORMER CONFORMED NAME:** Madrona Ventures, Inc.
- **DATE OF NAME CHANGE:** 20070108

**As filed with the Securities and Exchange Commission on March 13, 2023** 

------

**UNITED STATES** 

**SECURITIES AND EXCHANGE COMMISSION** 

**Washington, D.C. 20549** 

------

**FORM 15** 

------

**CERTIFICATION AND NOTICE OF TERMINATION OF REGISTRATION** 

**UNDER SECTION 12(g) OF THE SECURITIES EXCHANGE ACT OF 1934** 

**OR SUSPENSION OF DUTY TO FILE REPORTS UNDER SECTIONS 13 AND 15(d)**

**OF THE SECURITIES EXCHANGE ACT OF 1934.** 

**Commission File Number: 001-38193** 

------

## OPIANT PHARMACEUTICALS, INC.
**(Exact name of registrant as specified in its charter)** 

------

**10710 Midlothian Turnpike, Suite 125** 

**North Chesterfield, Virginia 23235** 

**(310) 598-5410** 

**(Address, including zip code, and telephone number, including area code, of registrant's principal executive offices)** 

**Common Stock, par value $0.001 per share** 

**(Title of each class of securities covered by this Form)** 

**None** 

**(Titles of all other classes of securities for which a duty to file reports under section 13(a) or 15(d) remains)** 

------

Please place an X in the box(es) to designate the appropriate rule provision(s) relied upon to terminate or suspend the duty to file reports:

---

| | |
|:---|:---|
|  Rule 12g-4(a)(1) | ☒ |
|  Rule 12g-4(a)(2) | ☐ |
|  Rule 12h-3(b)(1)(i) | ☒ |
|  Rule 12h-3(b)(1)(ii) | ☐ |
|  Rule 15d-6 | ☐ |
|  Rule 15d-22(b) | ☐ |

---

Approximate number of holders of record as of the certification or notice date: One (1).\*

\* <u>Explanatory Note</u>: Effective as of March 2, 2023, Opiant Pharmaceuticals, Inc. ("<u>Opiant</u>") merged with and into Olive Acquisition Subsidiary, Inc., a Delaware corporation ("<u>Merger Sub</u>") and a wholly owned subsidiary of Indivior Inc., a Delaware corporation ("<u>Parent</u>") and a wholly owned subsidiary of Indivior PLC, with Opiant surviving as a wholly owned subsidiary of Parent pursuant to that certain Agreement and Plan of Merger dated as of November 13, 2022 by and among Opiant, Parent, and Merger Sub. 

------

Pursuant to the requirements of the Securities Exchange Act of 1934, Opiant Pharmaceuticals, Inc., has caused this certification/notice to be signed on its behalf by the undersigned duly authorized person.

---

| | | |
|:---|:---|:---|
| Date: March 13, 2023 |  |  |
|  | **Opiant Pharmaceuticals, Inc.** | **Opiant Pharmaceuticals, Inc.** |
|  | By: | /s/ Ryan Preblick |
|  | Name: | Ryan Preblick |
|  | Title: | Chief Financial Officer, Secretary |
|  |  | and Treasurer |

---